Articles from Amalgam Rx, Inc.

Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rates to 84% in 2024, exceeding national benchmarks and surpassing the National Colorectal Cancer Roundtable’s 80% screening goal.

Amalgam Rx, Inc., a leading provider of AI-powered software for regulated medical devices, announced its collaboration with Biolinq Incorporated in developing the digital backbone for Biolinq Shine™, the first fully autonomous, needle-free glucose sensor recently granted De Novo Classification by the U.S. Food and Drug Administration (FDA).

Amalgam Rx, Inc., a leader in enabling data-driven healthcare decision making, today announced a $20 million credit investment from Catalio Capital Management, a leading investment firm dedicated to backing innovative healthcare companies. The funding will accelerate the scaling of Amalgam’s Medical-Grade AI solutions to further empower patients in their daily lives and providers in their clinical workflows.

Amalgam Rx, Inc., a leader in enabling data-driven health care decision making, announced the participation of CVS Health Ventures in its Series B investment round. The investment supports the scaling of Amalgam’s EHR-integrated clinical decision support platform to provide actionable information for health care providers (HCPs) for use at the point of care. Amalgam’s technology aligns and helps realize shared savings agreements between payers and HCPs.

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the expansion of its global agreement with Novo Nordisk for the commercialization of Dose Check. The new agreement bolsters the existing partnership and product suite between Novo Nordisk and Amalgam by incorporating and integrating with connected insulin delivery devices, continuous glucose monitors, and electronic health records (EHRs). Novo Nordisk is also making an equity investment in Amalgam.

Amalgam Rx, Inc., a leader in connecting healthcare providers, payers, and life sciences companies through a SaaS-enabled digital marketplace and product platform, and Privia Health Group, Inc., a national physician enablement company, announced a collaboration for multiple EHR-integrated services.

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, announced a collaboration with the AWS for Health initiative from Amazon Web Services (AWS) to accelerate the development and global commercialization of regulated digital solutions designed to transform healthcare delivery and improve patient outcomes and costs.

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformité Européenne (CE) Mark for its insulin titration application, iSage Rx™ and its white-labeled variants. The CE Mark demonstrates Amalgam's commitment to EU standards for quality management, safety, and performance as defined in the Medical Devices Directive 93/42/EEC.

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the acquisition of the assets of Geetha, LLC, an adaptive, conversational AI company. The acquisition bolsters Amalgam’s data science assets, which already include more than 6 billion longitudinal data points on millions of patients cared for across Amalgam’s technology platforms.